Plus + Client Login

Forgotten password?

Login

News

TGA Releases Update on Brexit and Implications for Therapeutic Goods in Australia

6th Mar 19

Summary —

The Therapeutic Goods Administration (TGA) has released an update on Brexit and the implications for therapeutic goods in Australia under any of the possible agreements that could occur.

Key issues for the dental industry —

The Australian Dental Industry Association (ADIA) has previously advised that Brexit offers no advantages for Australian’s dental industry. Further to this, the TGA has now released the following advice for the implications of any of the potential Brexit ‘deals’:

Brexit ‘no deal’

In the event of a ‘no deal’ exit of the United Kingdom (UK) from the European Union (EU), the TGA will implement transitional arrangements to provide for minimal interruption in the supply of medical devices in Australia.

The Medicines & Healthcare Products Regulatory Agency (MHRA) is the UK regulator for medical devices. They have released details of contingency legislation on their website, to ensure continued regulatory oversight and uninterrupted supply of medical devices in the event of a 'no deal' scenario.

If there is a ‘no deal’ Brexit, the TGA will continue accepting conformity assessment documents issued by UK notified bodies for existing products while these remain current for the purposes of UK market authorisation. This will apply to both existing Australian Register of Therapeutic Goods (ARTG) entries and applications for new inclusions of medical devices in ARTG:

• Medical devices currently included in ARTG may continue to be imported and/or supplied in Australia with the current certification issued by UK notified bodies, which are subject to continuing MHRA oversight.
• Two instruments will be amended to allow new applications for ARTG inclusion to proceed with conformity assessment documents issued by UK notified bodies:
  • The Therapeutic Goods (Overseas Regulators) Determination 2018 will be amended to include recognition of notified bodies granted ongoing legal status by the MHRA.
  • The Therapeutic Goods (Medical Devices – Information that Must Accompany Application for Inclusion) Determination 2018 will be amended to specify the conformity assessment documents issued by UK notified bodies that may accompany an application for inclusion in the ARTG.

Brexit ‘deal’ or exit extension

Under the proposed Brexit ‘deal’, UK notified bodies would continue to be recognised for a transition period through to 31 December 2020, so there will be no immediate impact on manufacturers certified by these notified bodies. Sponsors of these devices can continue providing these certificates as conformity assessment documents for their medical devices in Australia. Similarly, if the timeframe for the exit of the UK from the EU is extended, current arrangements will continue until an exit occurs.

Mutual Recognition Agreement (MRA)

Separate arrangements under the Mutual Recognition Agreement (MRA) with the EU also provide for recognition of certification issued under that agreement to be recognised in Australia and Europe, and this supports a small number of medical device approvals in Australia and provides for some Australian medical devices to be supplied in Europe.

The MRA treaty is managed by the Department of Industry, Innovation and Science, who have issued the following statement:

• Preparing for Brexit

Updating Manufacturer Evidence

Some notified bodies have arranged or are arranging to transfer EU certificates from UK notified bodies to EU notified bodies (for example, BSI UK to the recently accredited BSI Netherlands).

In such cases where manufacturers now have EU certificates issued by a notified body accredited in one of the EU member states, sponsors may apply to the TGA requesting change of the current certificate.

A standard process for variation of the Manufacturer Evidence (submitting a Manufacturer Evidence application to the TGA) will apply. If replacement of certificates results in the need to correct information entered on the ARTA, a Device Change Request will also be required.

The TGA has also provided external links for further information on its website. You can access these by clicking on the following link:

• Brexit – Implication for therapeutic goods in Australia

Member Engagement —

The ADIA Policy Team receives advice and guidance on matters concerning dental product regulation from members serving on the ADIA-PRPC Product Regulation Policy Committee.

Further information —

To keep up to date with all matters associated with dental product regulation follow ADIA on Facebook at www.facebook.com/dental.industry or the Twitter feed @AusDental. For further information on ADIA's engagement with the TGA on regulation send an email to policy@adia.org.au or telephone 1300 943 093.

Currency & Disclaimer —

This update was issued on 6 March 2019 and please note that changes in circumstances after the publication of material or information may impact upon its accuracy and also change regulatory compliance obligations. The statements, regulatory and technical information contained herein are believed to be accurate and are provided for information purposes only. Readers are responsible for assessing its relevance and verifying the accuracy of the content. To the fullest extent permitted by law, ADIA will not be liable for any loss, damage, cost or expense incurred in relation to or arising as a result of relying on the information presented here. 

This publication is available for your use under a Creative Commons Attribution 3.0 Australia licence, with the exception of the ADIA logo, other images and where otherwise stated. 

A —.. A D I A . .S T R A T E G I C . .A L L I A N C E S

Home > News